Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update

$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
5
Translate
Report
2669 Views
Comment
Sign in to post a comment
2705Followers
29Following
37KVisitors
Follow